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Background: Cardiology consults in cancer centers are often generated by atrial arrhythmias (AA). It is not well established which chemotherapy is 
associated with the highest AA rate.
Methods: We retrospectively reviewed the data on patients who received hematopoietic stem cell transplant (HSCT) in 1998-2005 and compared 
the proportion of patients who developed AA based on the drug regimen. Fisher’s chi square test and Student’s t-test were used for comparison of 
categorical and continuous variables, respectively.
Results: In 1998-2005 there were 1221 HSCTs, 62 (5.1%) of which were complicated by AA. Only melphalan demonstrated significantly higher rate 
of AA than any other chemotherapy. Out of 438 patients who received melphalan, 48 (11%) developed atrial fibrillation (AF) (35) or supraventricular 
tachycardia (13) during same hospital admission, and 390 did not (Table). Patients with AA were older (62.8 ±7.9 versus 55.5 ±10.2, p<0.001). 
Concomitant hypertension was associated with higher rate of AA. Length of stay was greater (24.9 ±8.9 days versus 19.6 ±5.8 days, p<0.0001) in 
those who developed AA, even after adjustment for co-morbidities.
Conclusion: Atrial arrhythmias, mostly AF, complicate about 5% of chemotherapeutic treatments used with HSCT. Melphalan is most 
arrhythmogenic and is associated with atrial arrhythmias in 11% of patients. Atrial arrhythmias are more common in patients with increased age and 
concomitant hypertension and result in about a four day increase in length of hospital stay. 
Table: Co-morbidities and Length of Stay in Melphalan Cases.
AF/SVT No AF/SVT
N % N % p
(48) (100) (390) (100)
Hypertension 25 52.1% 122 31.3% <0.01
Diabetes Mellitus 4 8.3% 23 5.9% NS
Coronary artery disease 3 6.3% 10 2.6% NS
Hemodialysis 4 8.3% 9 2.3% NS
White 42 87.5 322 82.5% NS
Black 4 8.3% 33 8.5% NS
Hispanic 2 4.2% 35 9.0% NS
Female 27 56.3% 174 44.6% NS
Male 21 43.8% 216 55.4% NS
Length of stay unadjusted 24.9 ± 8.9 19.6 ± 5.8 P<0.0001
Length of stay adjusted for co-morbidities 23.7 ± 5.2 19.4 ± 5.5 P<0.0001
